Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL953414 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2994601 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2998727 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2996449 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL4628774 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2991651 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2996446 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL2998728 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA7CHRNA4L3MBTL1CHRM5 | |
| SCHEMBL943172 | 0.94 | MEN1 (0.39) | CHRNB2CHRNA7CHRNA4L3MBTL1PARP1 | |
| Proline SCHEMBL28261914 | 0.86 | GRIN2D (0.35) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3688007-A1 | BIOCONJUGATION OF POLYPEPTIDES | The University of York (GB) | 2020-08-05 | — | — | EP | claimed |
| WO-2019063958-A1 | BIOCONJUGATION OF POLYPEPTIDES | THE UNIVERSITY OF YORK (GB) | 2019-04-04 | — | — | WO | claimed |
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| EP-4413985-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2024-08-14 | — | — | EP | disclosed |
| EP-3688007-B1 | BIOCONJUGATION OF POLYPEPTIDES | UNIV YORK (GB) | 2024-07-31 | — | — | EP | disclosed |
| CN-111494395-B | Carbidopa and levodopa prodrugs and their use for treating parkinson's disease | 艾伯维公司 | 2024-06-21 | — | — | CN | disclosed |
| US-11897917-B2 | Bioconjugation of polypeptides | THE UNIVERSITY OF YORK (GB) | 2024-02-13 | — | — | US | disclosed |
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | ABBVIE INC (US) | 2024-01-25 | — | — | US | disclosed |
| EP-3421454-B9 | PIPERIDINE DERIVATIVE | OTSUKA PHARMA CO LTD (JP) | 2023-08-09 | — | — | EP | disclosed |
| EP-4186510-A1 | INTERMEDIATES AND PROCESS FOR PREPARING L-DOPA DIPHOSPHATE | AbbVie Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| CN-116102537-A | Quinolinone derivative and preparation method and application thereof | 四川大学 | 2023-05-12 | — | — | CN | disclosed |
| EP-1717221-A1 | PROCESSES FOR PRODUCTION OF ALPHA-AMINOOXYKETONES AND ALPHA-HYDROXYKETONES | Japan Science and Technology Agency (JP) | 2006-11-02 | — | — | EP | disclosed |
| EP-1685119-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | Abbott Laboratories (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20060128706-A1 | Apoptosis promoters | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| WO-2006023720-A2 | REACTIONS OF ENOLIZABLE A-AMINO ALDEHYDES OR KETONES TO FORM AMINE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006007586-A1 | ORGANOCATALYSTS AND METHODS OF USE IN CHEMICAL SYNTHESIS | SCIENCE & TECHNOLOGY CORPORATION @ UNM (US) | 2006-01-19 | — | — | WO | disclosed |
| WO-2005090294-A2 | PROCESS OF MAKING α-AMINOOXYKETONE/α-AMINOOXYALDEHYDE AND α-HYDROXYKETONE/α-HYDROXYALDEHYDE COMPOUNDS AND A PROCESS OF MAKING REACTION PRODUCTS FROM CYCLIC α,ß-UNSATURATED KETONE SUBSTRATES AND NITROSO SUBSTRATES | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2005-09-29 | — | — | WO | disclosed |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2005-07-21 | — | — | US | disclosed |
| WO-2005049593-A2 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049594-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128706-A1 | Apoptosis promoters | BAX, BCL2, API5 | CHRNB2 3847/4885CHRNA7 4394/4885CHRNA4 4451/4885 |
| US-11897917-B2 | Bioconjugation of polypeptides | PTMS, EPCAM, IAPP | CHRNB2 2573/4885CHRNA7 4158/4885CHRNA4 4032/4885 |
| US-20050159427-A1 | N-acylsulfonamide apoptosis promoters | BAX, API5, CCAR2 | CHRNB2 4124/4885CHRNA7 4461/4885CHRNA4 4506/4885 |
| US-20240024338-A1 | CARBIDOPA AND L-DOPA PRODRUGS AND METHODS OF USE | COMT, SNCA, PARK7 | CHRNB2 172/4885CHRNA7 221/4885CHRNA4 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.